Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
Trial · NCT00957684
Participant flow50
How many started, completed or left each group, period by period.
1 to 20 of 50
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| PART I | STARTED | ESL 1200 mg Once Daily | 102 | |
| PART I | STARTED | ESL 800 mg Once Daily | 98 | |
| PART I | STARTED | ESL 400 mg Once Daily | 100 | |
| PART I | STARTED | Placebo | 102 | |
| PART I | STARTED | ESL - Part II | 0 | |
| PART I | Randomised (Safety Population) | ESL 1200 mg Once Daily | 102 | |
| PART I | Randomised (Safety Population) | ESL 800 mg Once Daily | 98 | |
| PART I | Randomised (Safety Population) | ESL 400 mg Once Daily | 100 | |
| PART I | Randomised (Safety Population) | Placebo | 102 | |
| PART I | Randomised (Safety Population) | ESL - Part II | 0 | |
| PART I | Intention-to-treat (ITT) Population | ESL 1200 mg Once Daily | 98 | |
| PART I | Intention-to-treat (ITT) Population | ESL 800 mg Once Daily | 98 | |
| PART I | Intention-to-treat (ITT) Population | ESL 400 mg Once Daily | 99 | |
| PART I | Intention-to-treat (ITT) Population | Placebo | 102 | |
| PART I | Intention-to-treat (ITT) Population | ESL - Part II | 0 | |
| PART I | Per-protocol (PP)Population | ESL 1200 mg Once Daily | 72 | |
| PART I | Per-protocol (PP)Population | ESL 800 mg Once Daily | 86 | |
| PART I | Per-protocol (PP)Population | ESL 400 mg Once Daily | 94 | |
| PART I | Per-protocol (PP)Population | Placebo | 91 | |
| PART I | Per-protocol (PP)Population | ESL - Part II | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00957684/flow